NasdaqCM - Nasdaq Real Time Price USD

Vistagen Therapeutics, Inc. (VTGN)

0.1803 -0.0041 (-2.22%)

As of 10:16:00 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder

GlobeNewswire 1d ago

VTGN
-2.22%
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)

GlobeNewswire 3mo ago

SRXH

VTGN
-2.22%
Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs

GlobeNewswire 21d ago

VTGN
-2.22%
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

GlobeNewswire 1mo ago

VTGN
-2.22%
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

GlobeNewswire 1mo ago

VTGN
-2.22%
Vistagen to Present at Psych Congress 2026

GlobeNewswire 1mo ago

VTGN
-2.22%
Vistagen Appoints Douglas J. Williamson to its Board of Directors

GlobeNewswire 3mo ago

VTGN
-2.22%
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Business Wire 4mo ago

VTGN
-2.22%
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)

GlobeNewswire 1mo ago

ONCO

SRXH

XBOTF
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

GlobeNewswire 3mo ago

VTGN
-2.22%
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Business Wire 4mo ago

VTGN
-2.22%
Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight

PR Newswire 1mo ago

ABCL

VTGN
-2.22%

Performance Overview

Return	VTGN	S&P 500 (^GSPC)
YTD	-72.68%	+9.96%
1-Year	-95.47%	+10.17%
3-Year	-92.98%	+70.49%

U.S. markets close in 5h 41m

Vistagen Therapeutics, Inc. (VTGN)

Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder

SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)

Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen to Present at Psych Congress 2026

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight